Multidrug resistant Acinetobacter baumannii - The role of AdeABC (RND family) efflux pump in resistance to antibiotics

Folia Histochemica et Cytobiologica

Volumn 46, Issue 3, 2008, Pages 257-267

  Wieczorek, Piotr ^a   Sacha, Paweł ^a   Hauschild, Tomasz ^b   Zórawski, Marcin ^a   Krawczyk, Małgorzata ^a   Tryniszewska, Elzbieta ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Acinetobacter baumannii; AdeABC; Efflux pump; MDR; RND family

Indexed keywords

ABC TRANSPORTER; AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; BACTERIAL PROTEIN; BETA LACTAM DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; DNA TOPOISOMERASE; ERYTHROMYCIN; IMIPENEM; MEROPENEM; PHENYLALANYL ARGINYL BETA NAPHTHYLAMIDE; PHENYLALANYLARGININE 2 NAPHTHYLAMIDE; POLYMYXIN DERIVATIVE; PROTEIN ACRA; PROTEIN ACRB; PROTEIN ADEABC; PROTEIN PARC; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE; TIGECYCLINE; TOLC PROTEIN; TRIMETHOPRIM; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CARRIER PROTEIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; DEATH; EFFUSION; GENE CLUSTER; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HOSPITAL INFECTION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PROKARYOTE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SEQUENCE ANALYSIS; TREATMENT FAILURE; BIOLOGICAL MODEL; DRUG EFFECT; GENETICS; METABOLISM;

ACINETOBACTER BAUMANNII; EUKARYOTA; NEGIBACTERIA; POSIBACTERIA; PROKARYOTA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MEMBRANE TRANSPORT PROTEINS; MODELS, BIOLOGICAL;

EID: 58949096273     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-008-0056-x     Document Type: Review

References (143)

1. Adewoye L, Sutherland A, Srikumar R, Poole K. The mexR repressor of the mexAB-oprM multidrug efflux operon in Pseudomonas aeruginosa: characterization of mutations compromising activity. J Bacteriol. 2002;184:4308-4312.
2. Aendekerk S, Ghysels B, Cornelis P, Baysse C. Characterization of a new efflux pump, MexGHI-OpmD, from Pseudomonas aeruginosa that confers resistance to vanadium. Microbiology. 2002;148:2371-2381.
3. Aires JR, Köhler T, Nikaido H, Plésiat P. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother. 1999;43:2624-2628.
4. Aires JR, Nikaido H. Aminoglycosides are captured from both periplasm and cytoplasm by the AcrD multidrug efflux transporter of Escherichia coli. J Bacteriol. 2005;187:1923-1929.
5. Allen D, Hartman B. Acinetobacter species. In: Mandell GL, Bennett JE, Dolin R, ed. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, Conn: Churchil Livingstone; 2000:2339-2344.
6. Alonso A, Martinez JL. Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomons maltophilia. Antimicrob Agents Chemother. 2000;44:3079-3086.
7. Anstey NM, Currie BJ, Withnall KM. Community-acquired Acinetobacter pneumonia in the Northern Territory of Australia. Clin Infect Dis. 1992;14:83-91.
8. Baranova N, Nikaido H. The BaeSR two-component regulatory system activates transcription of the yegMNOB (mdtABCD) transporter gene cluster in Escherichia coli and increases its resistance to novobiocin and deoxycholate. J Bacteriol. 2002;184:4168-4176.
9. Batchelor E, Goulian M. Robustness and the cycle of phosphorylation and dephosphorylation in a two-component regulatory system. Proc Natl Acad Sci USA. 2003;100:691-696.
10. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996;9:148-165.
11. Borst P, Evers R, Kool M, Wijnholds J. The multidrug resistance protein family. Biochim Biophys Acta. 1999;1461:347-357.
12. Bouvet PJ, Grimont PA. Identification and biotyping of clinical isolates of Acinetobacter. Ann Inst Pasteur Microbiol. 1987;138:569-578.
13. Brown MH, Paulsen IT, Skurray RA. The multidrug efflux protein NorM is a prototype of a new family of transporters. Mol Microbiol. 1999;31:393-395.
14. Buckley AM, Webber MA, Cooles S et al. The AcrAB-TolC efflux system of Salmonella enterica serovar Typhimurium plays a role in pathogenesis. Cell Microbiol. 2006;8:847-856.
15. Centers for Disease Control and Prevention (CDC). Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR Morb Mortal Wkly Rep. 2004;53:1063-1066.
16. Chastre J, Trouillet JL. Problem pathogens (Pseudomonas aeruginosa and Acinetobacter). Semin Respir Infect. 2000;15:287-298.
17. Chau SL, Chu YW, Houang ET. Novel resistance-nodulation-cell division efflux system AdeDE in Acinetobacter genomic DNA group 3. Antimicrob Agents Chemother. 2004;48:4054-4055.
18. Chen J, Kuroda T, Huda MN, Mizushima T, Tsuchiya T. An RND-type multidrug efflux pump SdeXY from Serratia marcescens. J Antimicrob Chemother. 2003;52:176-179.
19. Chu YW, Chau SL, Houang ET. Presence of active efflux systems AdeABC, AdeDE and Ade XYZ in different Acinetobacter genomic DNA groups. J Med Microbiol. 2006;55:477-478.
20. Chuanchuen R, Narasaki CT, Schweizer HP. The MexJK efflux pump of Pseudomonas aeruginosa requires OprM for antibiotic efflux but not for efflux of triclosan. J Bacteriol. 2002;184:5036-5044.
21. Cisneros JM, Reyes MJ, Pachón J et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis. 1996;22:1026-1032.
22. Corbella X, Pujol M, Ayats J et al. Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii. Clin Infect Dis. 1996;23:329-334.
23. Davis KA, Moran KA, McAllister CK, Gray PJ. Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis. 2005;11:1218-1224.
24. Delihas N, Forst S. MicF: an antisense RNA gene involved in response of Escherichia coli to global stress factors. J Mol Biol. 2001;313:1-12.
25. Eguchi Y, Oshima T, Mori H et al. Transcriptional regulation of drug efflux genes by EvgAS, a two-component system in Escherichia coli. Microbiology. 2003;149:2819-2828.
26. Elkins CA, Mullis LB. Mammalian steroid hormones are substrates for the major RND- and MFS-type tripartite multidrug efflux pumps of Escherichia coli. J Bacteriol. 2006;188:1191-1195.
27. Elkins CA, Nikaido H. Substrate specificity of the RND-type multidrug efflux pumps AcrB and AcrD of Escherichia coli is determined predominantly by two large periplasmic loops. J Bacteriol. 2002;184:6490-6498.
28. Eswaran J, Koronakis E, Higgins MK, Hughes C, Koronakis V. Three's company: component structures bring a closer view of tripartite drug efflux pumps. Curr Opin Struct Biol. 2004;14:741-747.
29. Fierobe L, Lucet JC, Decré D et al. An outbreak of imipenem-resistant Acinetobacter baumannii in critically ill surgical patients. Infect Control Hosp Epidemiol. 2001;22:35-40.
30. Fournier PE, Vallenet D, Barbe Valerie et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet. 2006;2:62-72.
31. Fralick JA. Evidence that TolC is required for functioning of the Mar/ AcrAB efflux pump of Escherichia coli. J Bacteriol. 1996;178:5803-5805.
32. Fralick JA. Evidence that TolC is required for functioning of the Mar/ AcrAB efflux pump of Escherichia coli. J Bacteriol. 1996;178:5803-5805.
33. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis. 2001;32(Suppl 2):S104-113.
34. Getchell-White SI, Donowitz LG, Gröschel DH. The inanimate environment of an intensive care unit as a potential source of nosocomial bacteria: evidence for long survival of Acinetobacter calcoaceticus. Infect Control Hosp Epidemiol. 1989;10:402-407.
35. Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis. 2001;40:117-120.
36. Helling RB, Janes BK, Kimball H et al. Toxic waste disposal in Escherichia coli. J Bacteriol. 2002;184:3699-3703.
37. Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii. J Antimicrob Chemother. 2004;54:821-823.
38. Hirakata Y, Srikumar R, Poole K et al. Multidrug efflux systems play an important role in the invasiveness of Pseudomonas aeruginosa. J Exp Med. 2002;196:109-118.
39. Houang ET, Chu YW, Leung CM et al. Epidemiology and infection control implications of Acinetobacter spp. in Hong Kong. J Clin Microbiol. 2001;39:228-234.
40. Hsueh PR, Teng LJ, Chen CY et al. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis. 2002;8:827-832.
41. Hujer KM, Hujer AM, Hulten EA et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter spp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother. 2006;50:4114-4123.
42. Huys G, Cnockaert M, Nemec A, Swings J. Sequence-based typing of adeB as a potential tool to identify intraspecific groups among clinical strains of multidrug-resistant Acinetobacter baumannii. J Clin Microbiol. 2005;43:5327-5331.
43. Jakoniuk P, Wieczorek P, Sacha PT, Zalewska M, Leszczyńska K. Wrażliwoość in vitro na cefoperazon/sulbaktam wieloopornych szczepów Acinetobacter spp. Zakażenia. 2007; 2:50-54.
44. Jariyawat S, Sekine T, Takeda et al. The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999;290:672-677.
45. Jerse AE, Sharma ND, Simms AN, Crow ET, Snyder LA, Shafer WM. A gonococcal efflux pump system enhances bacterial survival in a female mouse model of genital tract infection. Infect Immun. 2003;71:5576-5582.
46. Jones HE, Holland IB, Jacq A, Wall T, Campbell AK. Escherichia coli lacking the AcrAB multidrug efflux pump also lacks nonproteinaceous, PHB-polyphosphate Ca2+ channels in the membrane. Biochim Biophys Acta. 2003;1612:90-97.
47. Köhler T, Epp SF, Curty LK, Pechere JC. Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol. 1999;181:6300-6305.
48. Köhler T, Michea-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechere JC. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol Microbiol. 1997;23:345-354.
49. Köhler T, van Delden C, Curty LK, Hamzehpour MM, Pechere JC. Overexpression of the MexEF-OprN multidrug efflux system affects cell-to-cell signaling in Pseudomonas aeruginosa. J Bacteriol. 2001;183:5213-5222.
50. Koretke KK, Lupas AN, Warren PV, Rosenberg M, Brown JR. Evolution of two-component signal transduction. Mol Biol Evol. 2000;17:1956-1970.
51. Koronakis V, Eswaran J, Hughes C. Structure and function of TolC: the bacterial exit duct for proteins and drugs. Annu Rev Biochem. 2004;73:467-489.
52. Koronakis V, Sharff A, Koronakis E, Luisi B, Hughes C. Crystal structure of the bacterial membrane protein TolC central to multidrug efflux and protein export. Nature. 2000;405:914-919.
53. Kumar A, Worobec EA. Cloning, sequencing and characterization of the SdeAB efflux pump of Serratia marcescsens. Antimicrob Agents Chemother. 2005;49:1495-1501.
54. Kumar A, Worobec EA. Fluoroquinolone resistance of Serratia marcescens: involvement of a proton gradient-dependent efflux pump. J Antimicrob Chemother. 2002;50:593-596.
55. Lacroix FJ, Cloeckaert A, Grépinet O et al. Salmonella typhimurium acrB-like gene: identification and role in resistance to biliary salts and detergents and in murine infection. FEMS Microbiol Lett. 1996;135:161-167.
56. Landman D, Quale JM, Mayorga D et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med. 2002;162:1515-1520.
57. Levin AS, Barone AA, Penço J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis. 1999;28:1008-1011.
58. Li XZ, Nikaido H, Poole K. Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1995;39:1948-1953.
59. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs. 2004;64:159-204
60. Li XZ, Zhang L, Poole K. SmeC, an outer membrane multidrug efflux protein of Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2002;46:333-343.
61. Li Y, Mima T, Komori Y et al. A new member of the tripartite multidrug efflux pumps, MexVW-OprM, in Pseudomonas aeruginosa. J Antimicrob Chemother. 2003;52:572-575.
62. Li YH, Tanno M, Itoh T, Yamada H. Role of the monocarboxylic acid transport system in the intestinal absorption of an orally active beta-lactam prodrug: carindacillin as a model. Int J Pharm. 1999;191:151-159.
63. Liang R, Fei YJ, Prasad PD et al. Human intestinal H+/peptide cotransporter. Cloning, functional expression, and chromosomal localization. J Biol Chem. 1995;270:6456-6463.
64. Lin J, Sahin O, Michel LO, Zhang Q. Critical role of multidrug efflux pump CmeABC in bile resistance and in vivo colonization of Campylobacter jejuni. Infect Immun. 2003;71:4250-4259.
65. Liu W, Liang R, Ramamoorthy S et al. Molecular cloning of PEPT 2, a new member of the H+/peptide cotransporter family, from human kidney. Biochim Biophys Acta. 1995;1235: 461-466.
66. Llanes C, Hocquet D, Vogne C, Benali-Baitich D, Neuwirith C, Plesiat P. Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously. Antimicrob Agents Chemother. 2004;48: 1797-1802.
67. Lomovskaya O, Warren MS, Lee A et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother. 2001;45:105-116.
68. Lortholary O, Fagon JY, Hoi AB et al. Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin Infect Dis. 1995;20:790-796.
69. Ma D, Alberti M, Lynch C, Nikaido H, Hearst JE. The local repressor AcrR plays a modulating role in the regulation of acrAB genes of Escherichia coli by global stress signals. Mol Microbiol. 1996;19:101-112.
70. Ma D, Cook DN, Alberti M, Pon NG, Nikaido H, Hearst JE. Genes acrA and acrB encode a stress-induced efflux system of Escherichia coli. Mol Microbiol. 1995;16:45-55.
71. Ma D, Cook DN, Alberti M, Pon NG, Nikaido H, Hearst JE. Molecular cloning and characterization of acrA and acrE genes of Escherichia coli. J Bacteriol. 1993;175:6299-6313.
72. Ma D, Cook DN, Hearst JE, Nikaido H. Efflux pumps and drug resistance in Gram-negative bacteria. Trends Microbiol. 1994;2:489-493.
73. Magnet S, Courvalin P, Lambert T. Resistance-nodulationcell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother. 2001;45:3375-3380.
74. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis. 2000;31:101-106.
75. Marchand I, Damier-Piolle L, Courvalin P, Lambert T. Expression of the RND-type efflux pump AdeABC in Acinetobacter-baumannii is regulated by the AdeRS two-component system. Antimicrob Agents Chemother. 2004;48:3298-3304.
76. Marger MD, Saier MH Jr. A major superfamily of transmembrane facilitators that catalyse uniport, symport and antiport. Trends Biochem Sci. 1993;18:13-20.
77. Masuda S, Takeuchi A, Saito H, Hashimoto Y, Inui K. Functional analysis of rat renal organic anion transporter OAT-K1: bidirectional methotrexate transport in apical membrane. 1999. FEBS Lett. 1;459:128-132.
78. Mazzariol A, Zuliani J, Cornaglia G, Rossolini GM, Fontana R. AcrAB efflux system: expression and contribution to fluoroquinolone resistance in Klebsiella spp. Antimicrob Agents Chemother. 2002;46:3984-3986.
79. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T. Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1999; 43:415-417.
80. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T. Expression in Escherichia coli of a new multidrug efflux pump, Mex XY, from Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1999; 43:415-417.
81. Nagakubo S, Nishino K, Hirata T, Yamaguchi A. The putative response regulator BaeR stimulates multidrug resistance of Escherichia coli via a novel multidrug exporter system, MdtABC. J Bacteriol. 2002;184:4161-4167.
82. Nemec A, Maixnerova M, van der Reijden TJK, van den Broek PJ, Dijkshoorn L. Relationship between the AdeABC efflux system gene content, netilmicin susceptibility and multidrug resistance in a genotypically diverse collection of Acinetobacter baumannii strains. J Antimicrob Chemother. 2007;60:483-489.
83. Nikaido H, Basina M, Nguyen V, Rosenberg EY. Multidrug efflux pump AcrAB of Salmonella typhimurium excretes only those beta-lactam antibiotics containing lipophilic side chains. J Bacteriol. 1998;180:4686-4692.
84. Nikaido H. How do exported proteins and antibiotics bypass the periplasm in gram-negative bacterial cells? Trends Microbiol. 2000; 8:481-483.
85. Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev. 2003;67:593-656.
86. Nishino K, Yamaguchi A. EvgA of the two-component signal transduction system modulates production of the yhiUV multidrug transporter in Escherichia coli. J Bacteriol. 2002;184: 2319-2323.
87. Okusu H, Ma D, Nikaido D. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J Bacteriol. 1996;178:306-308.
88. Pages JM, Masi M, Barbe J. Inhibitors of efflux pumps in Gram-negative bacteria. Trends Mol Med. 2005;11:382-389.
89. Pannek S, Higgins PG, Steinke P et al. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphtylmethyl)-piperazine and phenyl-arginine-β-naphtylamide. J Antimicrob Chemother. 2006;57:970-974.
90. Paulsen IT, Skurray RA, Tam R et al. The SMR family: a novel family of multidrug efflux proteins involved with the efflux of lipophilic drugs. Mol Microbiol. 1996;19:1167-1175.
91. Paulsen IT. Multidrug efflux pumps and resistance: regulation and evolution. Curr Opin Microbiol. 2003;6:446-451.
92. Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51:2065-2069.
93. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemoter. 2007;51: 3471-3484.
94. Perron K, Caille O, Rossier C, Van Delden C, Dumas JL, Köhler T. CzcR-CzcS, a two-component system involved in heavy metal and carbapenem resistance in Pseudomonas aeruginosa. J Biol Chem. 2004;279:8761-8768.
95. Pesci EC, Milbank JB, Pearson JP et al. Quinolone signaling in the cell-to-cell communication system of Pseudomonas aeruginosa. Proc Natl Acad Sci USA. 1999;96:11229-11234.
96. Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev. 2006;19:382-402.
97. Piddock LJV. Multidrug-resistance efflux pumps - not just for resistance. Nat Rev. 2006;4:629-636.
98. Poole K, Gotoh N, Tsujimoto H et al. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug resistant strains. Mol Microbiol. 1996;21:713-724.
99. Poole K, Krebes K, McNally C, Neshat S. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J Bacteriol. 1993;175:7363-7372.
100. Poole K, Tetro K, Zhao Q, Neshat S, Heinrichs D, Bianco N. Expression of the multidrug resistance operon mexA-mex-BoprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression. Antimicrob Agents Chemother. 1996;40:2021-2028.
101. Prouty AM, Brodsky IE, Falkow S, Gunn JS. Bile-salt-mediated induction of antimicrobial and bile resistance in Salmonella typhimurium. Microbiology. 2004;150:775-783.
102. Pumbwe L, Piddock LJV. Two efflux systems expressed simultaneously in multidrug-resistant Pseudomonas aeruginosa. Antimocrob Agents Chemother. 2000;44:2861-2864.
103. Rahmati S, Yang S, Davidson AL, Zechiedrich EL. Control of the AcrAB multidrug efflux pump by quorum-sensing regulator SdiA. Mol Microbiol. 2002;43:677-685.
104. Rao VV, Dahlheimer JL, Bardgett ME et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci USA. 1999;96:3900-3905.
105. Renau TE, Léger R, Flamme EM et al. Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorg Med Chem Lett. 2001;11:663-667.
106. Rhomberg PR, Jones RN, Sader HS. Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres. Int J Antimicrob Agents. 2004;23:52-59.
107. Ribera A, Ruiz J, Jimenez de Anta MT, Vila J. Effect of an efflux pump inhibitor on the MIC of nalidixic acid for Acinetobacter baumannii and Stenotrophomonas maltophilia clinical isolates. J Antimicrob Chemother. 2002;49:697-702.
108. Roberts MC. Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution. FEMS Microbiol Rev. 1996;19:1-24.
109. Rosenberg EY, Ma D, Nikaido H. AcrD of Escherichia coli is an aminoglycoside efflux pump. J Bacteriol. 2000;182:1754-1756.
110. Ruzin A, Keeney D, Bradford PA. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Antimicrob Chemother. 2007;59:1001-1004.
111. Saier MH Jr, Tam R, Reizer A, Reizer J. Two novel families of bacterial membrane proteins concerned with nodulation, cell division and transport. Mol Microbiol. 1994;11:841-847.
112. Saito K, Yoneyama H, Nakae T. nalB-type mutations causing the overexpression of the MexAB-OprM efflux pump are located in the mexR gene of the Pseudomonas aeruginosa chromosome. FEMS Microbiol Lett. 1999;179:67-72.
113. Schreckenberger PC, Daneshvar MI, Hollis DG. Acinetobacter, Achromobacter, Chryseobacterium, Moraxella, and other nonfermentative Gram-negative rods. In: Murray PR, ed. Manual of clinical microbiology. Washington, Conn: ASM Press; 2007:770-802.
114. Segal H, Garny S, Elisha BG. Is IS(ABA-1) customized for Acinetobacter? FEMS Microbiol Lett. 2005;243:425-429.
115. Seifert H, Dijkshoorn L, Gerner-Smidt P, Pelzer N, Tjernberg I, Vaneechoutte M. Distribution of Acinetobacter species on human skin: comparison of phenotypic and genotypic identification methods. J Clin Microbiol. 1997;35:2819-2825.
116. Sekine T, Cha SH, Tsuda et al. Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998;429:179-182.
117. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H. Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem. 1997;272:18526-18529.
118. Sekiya H, Mima T, Morita Y, Kuroda T, Mizushima T, Tsuchiya T. Functional cloning and characterization of a multidrug efflux pump, mexHI-opmD, from a Pseudomonas aeruginosa mutant. Antimicrob Agents Chemother. 2003;47: 2990-2992.
119. Stavri M, Piddock L, Gibbons S. Bacterial efflux pump inhibitors from natural sources. J Antimicrob Chemother. 2007;59:1247-1260.
120. Takeda M, Tojo A, Sekine T, Hosoyamada M, Kanai Y, Endou H. Role of organic anion transporter 1 (OAT1) in cephaloridine (CER)-induced nephrotoxicity. Kidney Int. 1999;56:2128-2136.
121. Thanabalu T, Koronakis E, Hughes C, Koronakis V. Substrate-induced assembly of a contiguous channel for protein export from E. coli: reversible bridging of an inner-membrane translocase to an outer membrane exit pore. EMBO J. 1998;16:6487-9646.
122. Thanassi DG, Cheng LW, Nikaido H. Active efflux of bile salts by Escherichia coli. J Bacteriol. 1997;179:2512-2518.
123. Touzé T, Eswaran J, Bokma E, Koronakis E, Hughes C, Koronakis V. Interactions underlying assembly of the Escherichia coli AcrAB-TolC multidrug efflux system. Mol Microbiol. 2004; 53:697-706.
124. Towner K. The genus Acinetobacter. In: Dworkin M, ed. The prokaryotes. New York, Conn: Springer; 2006:746-758.
125. Traub WH, Leonhard B. Serotyping of Acinetobacter baumannii and genospecies 3: an update. Med Microbiol Lett. 1994;3:120-127.
126. Tseng TT, Gratwick KS, Kollman J et al. The RND permease superfamily: an ancient, ubiquitous and diverse family that includes human disease and development proteins. J Mol Microbiol Biotechnol. 1999;1:107-125.
127. Tsuji A, Tamai I, Nakanishi M, Terasaki T, Hamano S. Intestinal brush-border transport of the oral cephalosporin antibiotic, cefdinir, mediated by dipeptide and monocarboxylic acid transport systems in rabbits. J Pharm Pharmacol. 1993;45:996-998.
128. Urakami Y, Okuda M, Masuda S, Saito H, Inui KI. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther. 1998;287:800-805.
129. Urban C, Segal-Maurer S, Rahal JJ. Considerations in control and treatment of nosocomial infections due to multidrug resistant Acinetobacter baumannii. Clin Infect Dis. 2003;36:1268-1274.
130. Van Bambeke F, Glupczynski Y, Plesiat P, Pechere JC, Tulkens PM. Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J Antimicrob Chemother. 2003;51:1055-1065.
131. Van Bambeke F, Michot JM, Tulkens PM. Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. J Antimicrob Chemother. 2003;51:1067-1077.
132. Van Looveren M, Goossens H; ARPAC Steering Group. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect. 2004;10:684-704.
133. van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther. 1999;290:153-157.
134. van Veen HW, Konings WN. The ABC family of multidrug transporters in microorganisms. Biochim Biophys Acta. 1998;1365:31-36.
135. Vila J, Marti S, Sanchez-Cespedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother. 2007;59:1210-1215.
136. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol. 2003;24:284-295.
137. Visalli MA, Murphy E, Projan SJ, Bradford PA. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother. 2003;47:665-669.
138. West AH, Stock AM. Histidine kinases and response regulator proteins in two-component signaling systems. Trends Biochem Sci. 2001;26:369-376.
139. Westbrock-Wadman S, Sherman DR, Hickey MJ et al. Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability. Antimicrob Agents Chemother. 1999;43:2975-2983.
140. Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis. 2000; 31:690-697.
141. Wong KK, Brinkman FS, Benz RS, Hancock RE. Evaluation of a structural model of Pseudomonas aeruginosa outer membrane protein OprM, an efflux component involved in intrinsic antibiotic resistance. J Bacteriol. 2001;183:367-74.
142. Zgurskaya HI, Nikaido H. Multidrug resistance mechanisms: drug efflux across two membranes. Mol Microbiol. 2000;37:219-225.
143. Zhang L, Li XZ, Poole K. SmeDEF multidrug efflux pump contributes to intrinsic multidrug resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2001;45:3497-3503.